Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 11/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | PRKCG | P05129 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | BLK | P51451 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879974 | 0.87 | AURKA (0.62) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL14024744 | 0.87 | MAPK8 (0.50) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL14024347 | 0.87 | AURKA (0.55) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL849257 | 0.86 | SYK (0.62) | AURKASYKKDRCDK1ROCK2 | |
| SCHEMBL3459130 | 0.85 | AURKA (0.61) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL4884256 | 0.85 | EGFR (0.63) | AURKASYKAURKBKDRCDK2 | |
| SCHEMBL4880413 | 0.83 | KDR (0.64) | AURKASYKKDRCDK1ROCK2 | |
| SCHEMBL14024362 | 0.81 | EPHB4 (0.52) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL14024361 | 0.81 | AURKA (0.51) | AURKASYKAURKBKDRCDK1 | |
| SCHEMBL4870564 | 0.81 | EGFR (0.47) | AURKASYKAURKBKDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | claimed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | AURKA 537/4885SYK 2248/4885AURKB 657/4885 |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | TYMS, KDR, FLT4 | AURKA 1098/4885SYK 2737/4885AURKB 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.